Cerus Corporation

Cerus Corporation, a for-profit biomedical products manufacturer headquartered in Concord, California, supplies pathogen reduction blood safety technologies to federal healthcare and defense agencies as a prime contractor (99% of recent awards) competing predominantly on a full-and-open, non-competitive basis. The company manufactures and services the INTERCEPT Blood System, a proprietary platform using riboflavin and ultraviolet light to inactivate pathogens in platelet, plasma, and red blood cell components; federal customers procure processing sets, storage containers, illuminator equipment, and maintenance services across military medical centers and civilian federal research hospitals.

Cerus operates in a concentrated, high-value customer base dominated by the Defense Health Agency and Department of Health and Human Services. The top five customer agencies by potential value account for 100% of combined awards, led by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (2 awards, $470.6 million combined potential value) and the Office of the Secretary of Defense (1 award, $25 million), with the Defense Health Agency placing the largest award count (34 awards, $12.6 million combined potential value), the Department of the Navy Bureau of Medicine and Surgery (16 awards, $1 million), and the National Institutes of Health Clinical Center (4 awards, $175 thousand). The potential-value ranking diverges sharply from award count: ASPR's two research and development awards dwarf DHA's 34 smaller procurement orders, signaling a portfolio split between sustained consumables supply to military medical facilities and significant development contracts for advanced blood component technologies.

Cerus's capability portfolio spans both product supply and applied research. Representative prime work includes a $188.4 million Other Transaction Agreement with ASPR (awarded September 2024, ultimate completion December 2030) for development and licensing of pathogen reduction technology for red blood cell components capable of treating over ten million units and reducing transfusion-transmitted infection risk; a $25 million Other Transaction Agreement with the Office of the Secretary of Defense (awarded September 2022, ultimate completion September 2028) for lyophilized pathogen-reduced cryoprecipitate manufacturing advancement; and recurring full-and-open purchase orders from the Defense Health Agency for INTERCEPT Platelet Processing Sets, illuminator maintenance, and drop-shipment supply across Naval Hospital Okinawa, Naval Base San Diego, Naval Hospital Guam, Tripler Army Medical Center, and Walter Reed National Military Medical Center, ranging from $5 thousand to $369 thousand per order. A single federal grant sub-award ties to the Coalition for National Trauma Research (awarded October 2024) for operationalization of pathogen-reduced plasma provision and thrombinogen analysis in a collaborative clinical study.

Recent activity shows acceleration and then stabilization: awards grew from two in 2022 to ten in 2024, then declined to eight in 2025 with one recorded award in 2026 to date. Eleven awards (combined potential value $283.7 million) reach ultimate completion within the next twenty-four months, representing significant recompete exposure—dominated by the two ASPR and OSD development contracts that anchor the portfolio's dollar value. Across all awards in source, combined potential value totals $520.9 million against $283.4 million obligated (54% obligation rate), reflecting the multi-year, long-tail structure of R&D development contracts and standing supply agreements.

Service Contract Inventory data captures a narrow slice of Cerus's federal service activity. SCI-reportable invoiced revenue in FY2024 totaled $19.3 million across 23.2 FTEs on prime contracts; FY2022 and FY2023 reported zero SCI-reportable service revenue and zero FTEs, consistent with Cerus's primary business model as a goods manufacturer rather than a services vendor. On the six SCI records in source, government-paid hourly rates remained flat across the spectrum—median $281.29/hr with minimal variance (10th percentile $280.58/hr, 90th percentile $282.01/hr)—and subcontractors averaged 13% of total contractor hours across reported prime contracts, with 17 named subcontractors engaged. SCI is an incomplete view of Cerus's federal footprint: the vast majority of the company's federal revenue flows from product sales and development contracts rather than time-and-materials service work, and total enterprise revenue extends well beyond federal customers and reported SCI activity.

Cerus operates as a pure-play sole-source supplier to military medicine and federal research hospitals. Award framing consistently cites FAR Simplified Acquisition Procedures (FAR 13) and unique technological capability justification; no competitive set-asides appear across the portfolio, and no vehicles (GWACs, BPAs, IDIQs) structure the relationship—purchases are direct purchase orders or definitive contracts. The company subcontracts minimally (1% of awards) and holds no named teaming relationships in the source data, indicating a vertically integrated delivery model built around its proprietary INTERCEPT technology platform and manufacturing capability rather than a subcontract feeder or systems integrator role.